Jamieson Wellness Unsolicited Bid|10x EBITDA Discount That Attracted a 2B Offer

Chapter 1: The Vitamin Company That Quietly Outgrew Its Own Stock Price

Jamieson Wellness shares jumped as high as $43 on Thursday after the company confirmed an unsolicited takeover offer — the first time the stock touched that level since late 2020. By early afternoon the shares had pulled back to $41.39, a gain of nearly 14 per cent over Wednesday's close, giving the company a market value above $1.7 billion. The immediate question is not whether Jamieson is a good company — the record is unambiguous on that. Revenue more than doubled from roughly $400 million in 2020 to over $820 million in 2025. Adjusted EBITDA climbed from around $100 million in 2021 to nearly $160 million last year. The company projects 2026 EBITDA will surpass $174 million. What the bid exposes is why an outside party had to force the market's hand: Jamieson's stock had spent years trading at a multiple below what the fundamentals support. The board confirmed it has hired BMO Capital Markets and Canaccord Genuity as advisers and is in talks with the original bidder and other interested parties. Management added the standard caveat — there is no assurance any transaction will result. That caveat is the bottleneck: the $43 intraday high and the $41 closing level are separated by how much weight holders assign to that single sentence.

Chapter 2: The Multiple Compression That Made Jamieson a Target

Royal Bank of Canada analyst Ryland Conrad, who carries a buy rating and a $46 price target on Jamieson, described the bid as "not overly surprising" given the company's valuation. The reason is specific: Jamieson has traded at 10 to 11 times EBITDA for years, despite an average historical multiple of 13.5x and comparable acquisition deals closing in the mid-teens. Each full multiple turn is worth roughly $4.50 per share, by Conrad's own calculation. That means the distance between today's trading price and where deal precedents say it should land is measured in a handful of multiples, not in fundamental execution gaps. The company's China operation makes the compression harder to justify. Chinese revenue was under $30 million in 2022, rose to $140 million in 2025, and is projected to reach at least $178 million in 2026 — making China Jamieson's second-largest market within four years of taking direct control of its distribution there. U.S. revenue followed a similar trajectory: $68 million in 2022, $147 million in 2025, projected at $162 to $170 million in 2026 after the Youtheory collagen acquisition. Two markets, both built from small bases through internal execution, now together approach the size of Jamieson's entire Canadian business. The buried assumption in the bear case is that a vitamin company's growth is Canada-bound and capped. The articles directly contradict that: two international segments are growing faster than the domestic core, and neither has hit an evident ceiling. What the market persistently failed to assign value to is a platform with demonstrated cross-border execution — precisely the asset a strategic acquirer in the global VMS space would pay a premium to own.

Chapter 3: Deal Arithmetic and What a Holder Watches Now

Potential acquirers named in analyst commentary include private equity and strategic buyers from the global vitamin, mineral, and supplement industry — names such as Nestle, Haleon, and Herbalife surface as plausible strategics. The deal math is straightforward given Conrad's framework: at 13.5x projected 2026 EBITDA of $174 million, the implied enterprise value approaches $2.35 billion. At mid-teens multiples — consistent with comparable deals — that rises further, potentially supporting a per-share price above $50. The counter-position is in the company's own words: "no assurance this process will result in any transaction." Jamieson's CEO stated as recently as May 7 that the company is "not desperate to do an acquisition" and has significant organic growth ahead — a management team confident in its standalone plan is also one that will not accept a below-fair-value bid. That creates a genuine standoff: the acquirer approaches at a price below the board's internal view of worth; the board runs a process that may attract higher bids or may end with no deal. For a holder: the question is not whether to sell today at $41 — it is whether the process produces a bid at 13x or higher, which would mean the current intraday price already prices only half the premium. The monitoring variable is the identity and structure of any formal offer that emerges from this process. A strategic acquirer paying mid-teens multiples prices in Jamieson's China and U.S. trajectories; a private equity buyer focused on near-term EBITDA would likely bid closer to 12x. Until that offer structure is disclosed, a holder's decision reduces to a single question: does the eventual bid price the international platform or only the trailing Canadian core? The answer is what decides whether $41 is an exit or an entry point.